Curaleaf Q1 revenue rises 6% gross margin declines

Curaleaf Holdings

05/05/2026 21:09

Overview

U.S. cannabis producer's Q1 revenue rose 6% yr/yr to $324 mln

Gross margin declined to 49%, adjusted EBITDA margin fell to 19.6%

Company completed buyout of German subsidiary Four 20 Pharma and changed auditors

Outlook

Curaleaf did not provide specific financial guidance for future quarters or the full year

Result Drivers

INTERNATIONAL GROWTH - International revenue rose 35% yr/yr, driven by expansion in Europe, including the buyout of German subsidiary Four 20 Pharma

RETAIL FOOTPRINT EXPANSION - Opened new dispensaries in Florida, Maine, and Ohio, increasing total U.S. store count to 164

PRODUCT LAUNCHES - Introduced Select Briq 2 vape in 12 states and launched ultra-premium Dark Heart flower brand in 11 states

Company press release: ID:nPn9KqmtTa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Adjusted EBITDA
$63 mln
Q1 Gross Profit
$157.30 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Curaleaf Holdings Inc is C$5.00, about 12.4% above its May 4 closing price of C$4.45

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)